Rhythm Pharmaceuticals officer proposes $913K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
RHYTHM PHARMACEUTICALS, INC. (RYTM) officer Alastair Garfield reported a proposed sale of 7,763 common shares, with an aggregate market value of $912,928.80 and an approximate sale date of August 13, 2026. The shares were acquired from the issuer as restricted stock units, with vesting during July 1, 2025 through February 1, 2026. The notice lists May 14, 2026 as the date of plan adoption or giving of instruction, if relying on Rule 10b5-1.
Key Figures
Key Terms
Restricted Stock Units financial
vesting financial
Rule 10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Rule 10b5-1 date appears in the RYTM notice?
AI-generated analysis. How Rhea-AI works. Not financial advice.